Equities

Maravai LifeSciences Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Maravai LifeSciences Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.99
  • Today's Change-0.13 / -4.17%
  • Shares traded634.42k
  • 1 Year change-29.81%
  • Beta0.3989
Data delayed at least 15 minutes, as of Feb 12 2026 19:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.

  • Revenue in USD (TTM)192.28m
  • Net income in USD-121.24m
  • Incorporated2020
  • Employees550.00
  • Location
    Maravai LifeSciences Holdings Inc10770 Wateridge Circle Suite 200Suite 200SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 546-0004
  • Fax+1 (302) 655-5049
  • Websitehttps://www.maravai.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jade Biosciences Inc0.00-65.26m742.67m4.00--2.74-----11.45-11.450.005.500.00----0.00-44.48-47.29-50.06-50.63-----------320.040.00------7.80------
Annexon Inc0.00-208.88m757.42m99.00--3.74-----1.39-1.390.001.400.00----0.00-68.11-42.65-76.07-45.54------------0.00-------2.95---43.78--
MiMedx Group Inc393.44m40.83m771.61m837.0019.083.2313.911.960.2730.2732.631.611.402.795.95470,062.1014.512.9417.633.8981.9983.0010.382.073.95--0.0708--8.523.12-24.73---5.37--
YD Bio Ltd-100.00bn-100.00bn779.26m5.00--153.15----------0.0722------------------------1.36--0.0124--45.76---10,509.73------
Kalvista Pharmaceuticals Inc15.12m-210.31m783.97m270.00--46.12--51.86-3.95-3.950.28380.33630.0604--1.5155,992.59-84.00-49.86-97.02-54.2187.95---1,391.14--7.21-82.770.9412-------44.85--33.39--
Janux Therapeutics Inc10.00m-101.90m788.54m74.00--0.8071--78.85-1.67-1.670.164916.240.0116----135,135.10-11.85-13.75-12.17-14.23-----1,018.95-743.21----0.00--30.99---18.36------
Personalis Inc69.10m-73.88m790.36m229.00--4.61--11.44-0.8761-0.87610.81891.930.28637.714.96301,759.80-30.61-29.82-36.03-34.6926.6728.44-106.92-105.714.69--0.0133--15.155.3524.94---28.17--
Upstream Bio Inc2.80m-122.77m793.83m52.00--2.10--283.61-2.30-2.300.05277.010.009--4.3453,826.92-39.18---40.67-------4,366.77------0.00---0.4202---99.70------
Omeros Corp0.00-121.24m796.21m202.00---------2.04-2.020.00-3.150.00----0.00-48.59-50.90-66.86-63.20------------2.72-------4.41---13.15--
Maravai Lifesciences Holdings Inc192.28m-121.24m797.81m550.00--3.25--4.15-0.8442-0.84421.340.9610.18083.187.48337,338.60-20.148.27-27.6810.4520.8672.61-111.4225.484.56-7.370.42880.00-10.3012.61-21.69--12.69--
Arbutus Biopharma Corp14.61m-42.28m800.07m44.00--10.32--54.78-0.2219-0.22190.07640.40320.1227--11.62331,954.50-35.50-44.03-39.50-49.46-----289.45-433.59----0.0454---65.980.52684.02---20.93--
MapLight Therapeutics Inc0.00-92.43m806.28m109.00---------2.23-2.230.001.54----------------------------0.00-------39.26------
Bicara Therapeutics Inc0.00-121.52m810.77m55.00--2.01-----5.03-5.030.007.380.00----0.00-25.61---26.61--------------0.00-------30.80------
BIOAGE Labs Inc5.92m-75.79m834.53m62.00--2.58--141.04-2.04-2.040.15947.740.0184----95,435.48-23.59---25.31-------1,280.90------0.0147-------11.36------
Arvinas Inc312.30m-58.50m840.70m430.00--1.64--2.69-0.8048-0.80484.307.970.3105--22.63726,279.10-5.82-20.58-7.36-25.05-----18.73-211.50----0.0007--235.5443.7145.85---22.02--
Data as of Feb 12 2026. Currency figures normalised to Maravai LifeSciences Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

42.67%Per cent of shares held by top holders
HolderShares% Held
12 West Capital Management LPas of 30 Sep 202512.52m8.63%
Braidwell LPas of 30 Sep 20258.35m5.76%
BlackRock Fund Advisorsas of 30 Sep 20257.69m5.30%
The Vanguard Group, Inc.as of 31 Dec 20256.34m4.37%
T. Rowe Price Investment Management, Inc.as of 30 Sep 20256.16m4.25%
Mackenzie Financial Corp.as of 30 Sep 20256.07m4.19%
Renaissance Technologies LLCas of 30 Sep 20254.32m2.98%
Mirabella Financial Services LLPas of 30 Sep 20253.75m2.59%
Monaco Asset Management SAMas of 30 Sep 20253.66m2.52%
Tejara Capital Ltd.as of 31 Dec 20253.02m2.08%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.